Vor Biopharma, Inc. VOR 深 沪
等待开盘 07-02 09:30:00 美东时间
18.39
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 18.39
- 总市值 9.96亿
- 52周最高 53.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.50
- 委 比 0.00%
- 总股本 5418.59万
- 历史最高 1272.40
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.622
- 每 手 1
- 风险率 12.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vor Biopharma shareholders back directors and governance measures
The latest update is out from Vor Biopharma ( ($VOR) ). At its 2026 Annual Meet...
06-13 04:39
Vor Bio Announces Conditional China National Medicinal Products Administration Approval Of Telitacicept For The Treatment Of Adult Patients With IgAN
The conditional approval is supported by positive efficacy and safety data from RemeGen's completed Phase 2 trial (18C014) and Phase 3 TELIGAN trial (18C021 Part A) in IgAN. RemeGen independently developed telitacicept
06-08 20:33
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study....
06-05 00:33
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio granted stock options for 61,050 shares and RSUs for 12,900 shares to 10 new employees on June 1, 2026, under the 2023 Inducement Plan. The options have a $14.57 exercise price, a 10-year term, and vest over four years, with 25% after 12 months and the rest monthly. RSUs vest similarly but quarterly. Both are subject to continued employment and the terms of the Inducement Plan.
06-01 21:00
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $15 to $18.
05-14 21:19
Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 85.96 percent increase over losses of $(5.20) per share from the
05-13 20:57
Vor Biopharma Q1 net loss widens
Vor Biopharma Q1 net loss widens Overview U.S. biotech firm's Q1 net loss widened R&D expenses fell yr/yr, mainly due to reduced spend on previous programs and lower headcount Company ended Q1 with $491.5 mln in cash, expected to fund operations into early 2029 Outlook Company's cash and investments
05-13 20:38
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
